Literature DB >> 18157513

Skewed X-chromosome inactivation in scleroderma.

Elif Uz1, Laurence S Loubiere, Vijayakrishna K Gadi, Zeynep Ozbalkan, Jeffrey Stewart, J Lee Nelson, Tayfun Ozcelik.   

Abstract

Scleroderma is a female-prevalent autoimmune disease of unclear etiology. Two fundamental gender differences, skewed X-chromosome inactivation (XCI) and pregnancy-related microchimerism, have been implicated in scleroderma. We investigated the XCI patterns of female scleroderma patients and the parental origin of the inactive X chromosome in those patients having skewed XCI patterns (>80%). In addition, we investigated whether a correlation exists between XCI patterns and microchimerism in a well-characterized cohort. About 195 female scleroderma patients and 160 female controls were analyzed for the androgen receptor locus to assess XCI patterns in the DNA extracted from peripheral blood cells. Skewed XCI was observed in 67 (44.9%) of 149 informative patients and in 10 of 124 healthy controls (8.0%) [odds ratio (OR) = 9.3 (95% confidence interval (CI) 4.3-20.6, P < 0.0001)]. Extremely skewed XCI (>90%) was present in 44 of 149 patients (29.5%) but only in 3 of 124 controls (2.4%; OR = 16.9; 95% CI 4.8-70.4, P < 0.0001). Parental origin of the inactive X chromosome was investigated for ten patients for whom maternal DNA was informative, and the inactive X chromosome was of maternal origin in eight patients and of paternal origin in two patients. Skewed XCI mosaicism could be considered as an important risk factor in scleroderma.

Entities:  

Mesh:

Year:  2008        PMID: 18157513      PMCID: PMC2716291          DOI: 10.1007/s12016-007-8044-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  16 in total

1.  Age- and tissue-specific variation of X chromosome inactivation ratios in normal women.

Authors:  A Sharp; D Robinson; P Jacobs
Journal:  Hum Genet       Date:  2000-10       Impact factor: 4.132

2.  X inactivation in females with X-linked disease.

Authors:  J M Puck; H F Willard
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Predominance of autoimmune and rheumatic diseases in females.

Authors:  R E Kast
Journal:  J Rheumatol       Date:  1977       Impact factor: 4.666

4.  Microchimerism and HLA-compatible relationships of pregnancy in scleroderma.

Authors:  J L Nelson; D E Furst; S Maloney; T Gooley; P C Evans; A Smith; M A Bean; C Ober; D W Bianchi
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

5.  Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.

Authors:  L Busque; R Mio; J Mattioli; E Brais; N Blais; Y Lalonde; M Maragh; D G Gilliland
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

Review 6.  Estrogens and autoimmune diseases.

Authors:  Maurizio Cutolo; Silvia Capellino; Alberto Sulli; Bruno Serioli; Maria Elena Secchi; Barbara Villaggio; Rainer H Straub
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

Review 7.  Systemic sclerosis: current views of its pathogenesis.

Authors:  Chris T Derk; Sergio A Jimenez
Journal:  Autoimmun Rev       Date:  2003-06       Impact factor: 9.754

8.  Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune?

Authors:  J L Nelson
Journal:  Arthritis Rheum       Date:  1996-02

9.  Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation.

Authors:  R C Allen; H Y Zoghbi; A B Moseley; H M Rosenblatt; J W Belmont
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

10.  Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of healthy women and women with scleroderma.

Authors:  Nathalie C Lambert; Timothy D Erickson; Zhen Yan; Jennifer M Pang; Katherine A Guthrie; Daniel E Furst; J Lee Nelson
Journal:  Arthritis Rheum       Date:  2004-03
View more
  16 in total

1.  Can maternal microchimeric cells influence the fetal response toward self antigens?

Authors:  Lucie Leveque; Kiarash Khosrotehrani
Journal:  Chimerism       Date:  2011-07-01

Review 2.  Unraveling the genetic component of systemic sclerosis.

Authors:  José Ezequiel Martín; Lara Bossini-Castillo; Javier Martín
Journal:  Hum Genet       Date:  2012-01-05       Impact factor: 4.132

3.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

4.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 5.  Epigenetics and systemic sclerosis.

Authors:  Nezam Altorok; Bashar Kahaleh
Journal:  Semin Immunopathol       Date:  2015-07-11       Impact factor: 9.623

6.  Mechanisms and pathophysiology of autoimmune disease.

Authors:  Wesley H Brooks
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 7.  The X chromosome in immune functions: when a chromosome makes the difference.

Authors:  Claude Libert; Lien Dejager; Iris Pinheiro
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

Review 8.  Epigenetics in rheumatoid arthritis.

Authors:  Michelle Trenkmann; Matthias Brock; Caroline Ospelt; Steffen Gay
Journal:  Clin Rev Allergy Immunol       Date:  2010-08       Impact factor: 8.667

9.  X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma.

Authors:  C Selmi; C A Feghali-Bostwick; A Lleo; S A Lombardi; M De Santis; F Cavaciocchi; L Zammataro; M M Mitchell; J M Lasalle; T Medsger; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

Review 10.  Why are women predisposed to autoimmune rheumatic diseases?

Authors:  Jacqueline E Oliver; Alan J Silman
Journal:  Arthritis Res Ther       Date:  2009-10-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.